Ozempic Reduces Kidney Disease Risks and Mortality in Diabetics: Study

A new study published in the New England Journal of Medicine reveals that weekly injections of semaglutide, such as Ozempic, significantly reduce the risk of severe kidney outcomes, major cardiovascular events, and death in people with type 2 diabetes and chronic kidney disease. The trial, involving about 3,500 participants, showed a 24% reduction in severe outcomes and additional benefits like slower kidney function decline and lower risk of heart attacks and death. The study highlights the potential of semaglutide as a transformative treatment for diabetic kidney disease, though access to the drug remains a challenge for high-risk groups.